Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Vertex Pharmaceuticals Inc. ( (VRTX)) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors. Vertex Pharmaceuticals Inc., a ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Phil Nadeau, an analyst from TD Cowen, maintained the Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price target remains the same with $525.00. Phil Nadeau’s ...

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX) in the last three months. In the table below ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

While there are several candidates to make the next stock split announcement, Vertex Pharmaceuticals (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4. Just because a stock ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated more than 40% since I shifted my coverage to hold/neutral last year, and I am not surprised since the company executed ...

In the preceding three months, 19 analysts have released ratings for Vertex Pharmaceuticals VRTX, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...